480 related articles for article (PubMed ID: 31718534)
21. Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan.
Su WJ; Chuang PH; Chang LY; Lo HY; Chiang CS; Wang ET; Yang CH
BMC Infect Dis; 2021 Jan; 21(1):45. PubMed ID: 33423657
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
Falkenhorst G; Remschmidt C; Harder T; Hummers-Pradier E; Wichmann O; Bogdan C
PLoS One; 2017; 12(1):e0169368. PubMed ID: 28061505
[TBL] [Abstract][Full Text] [Related]
24. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
26. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
Wijayasri S; Hillier K; Lim GH; Harris TM; Wilson SE; Deeks SL
PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
[TBL] [Abstract][Full Text] [Related]
27. Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets.
Moens L; Verbinnen B; Covens K; Wuyts G; Johnson M; Roalfe L; Goldblatt D; Meyts I; Bossuyt X
Infect Immun; 2015 Jul; 83(7):2889-96. PubMed ID: 25939510
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
[TBL] [Abstract][Full Text] [Related]
29. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
30. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
[TBL] [Abstract][Full Text] [Related]
32. Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals.
Nived P; Jørgensen CS; Settergren B
Vaccine; 2015 Mar; 33(14):1688-94. PubMed ID: 25707692
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
34. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
35. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster.
Papadatou I; Lagousi T; Kattamis A; Spoulou V
Ann Hematol; 2019 Mar; 98(3):775-779. PubMed ID: 30683996
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
Belmonti S; Rossetti B; Modica S; Paglicci L; Borghetti A; Ciccullo A; Picarelli C; Cauda R; De Luca A; Montagnani F; Lombardi F
Infect Dis Ther; 2019 Sep; 8(3):453-462. PubMed ID: 31364010
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13 in COPD patients over a 5-year follow-up cohort study.
Ignatova GL; Avdeev SN; Antonov VN
Sci Rep; 2021 Aug; 11(1):15948. PubMed ID: 34354113
[TBL] [Abstract][Full Text] [Related]
39. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
Dunne EM; Cilloniz C; von Mollendorf C; Lewnard J; Grant LR; Slack MPE; Jodar L; Theilacker C; Gessner BD
Arch Bronconeumol; 2023 Mar; 59(3):157-164. PubMed ID: 36681604
[TBL] [Abstract][Full Text] [Related]
40. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]